ArticleInternational journal of cancer2025
Time to pathologic diagnosis of suspicious breast lesions: An institution-based study in five Ethiopian hospitals.
Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07023198 (Provider-Initiated Screening Clinical Breast Examination and Patient Navigation in Sub-Saharan Africa), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Provider-Initiated Screening Clinical Breast Examination and Patient Navigation in Sub-Saharan Africa
Who cites it
2 citing papers in PubMed.
- Access and time to chemotherapy among Ethiopian cancer patients: a population-based registry study.The oncologist · 2026Article
- Time to pathologic diagnosis of suspicious breast lesions: An institution-based study in five Ethiopian hospitals.International journal of cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Most breast cancer (BC) patients in sub-Saharan Africa are diagnosed at advanced stages. The World Health Organization's Global Breast Cancer Initiative Pillar II has a benchmark to diagnose BC within 2 months of the first contact with a health care provider (HCP). In this study, we interviewed 345 women who received a diagnostic workup of a suspicious breast lesion (eventually diagnosed as benign or malignant) at five Ethiopian hospitals in 2022. We assessed the length of the diagnostic journey encompassing the pre-contact interval between the first experience of symptoms and the first HCP visit, and the post-contact interval between HCP visit and diagnostic pathology procedures. We used negative binomial regression models to identify factors influencing these time intervals. The median pre-contact interval was 2.8 months (interquartile range [IQR] 0.5-9.8). The median post-contact interval was 1.7 months (IQR 0.6-3.9). Regarding the post-contact interval, 55% of patients received their pathologic diagnosis within the recommended 2 months after the first HCP visit and met the Global Breast Cancer Initiative's benchmark. Increased travel times, limited social support, and consulting multiple HCPs before seeking pathology evaluation prolonged post-contact intervals. Older patients (>45 years) and those referred for pathology evaluation during the initial HCP visit experienced shorter post-contact intervals. Of all 345 women, 39% were diagnosed with BC. The relatively low proportion of women diagnosed within the recommended time frame makes it evident that increased awareness for BC, easily accessible diagnostic services, and specific training for HCPs are essential for the timely diagnosis of BC in Ethiopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.